Gilead, Merck Hook Up In Long-Anticipated HIV Drug Deal, Stoking SharesInvestors Business Daily • 03/15/21
Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIVBusiness Wire • 03/15/21
Roche's Tocilizumab, Gilead's Remdesivir Combo Fails To Improve Hospital Discharge Time in COVID-19 StudyBenzinga • 03/11/21
Gilead's Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROIBusiness Wire • 03/09/21
Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults in Four-Year Data Presented at CROIBusiness Wire • 03/06/21
U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic TherapyBusiness Wire • 03/06/21
Gilead Sciences, Inc. (GILD) Presents at Cowen 41st Annual Health Care Conference (Transcript)Seeking Alpha • 03/04/21
Gilead to Present New Data at CROI 2021 Demonstrating the Company's Commitment to Addressing Urgent Global Health NeedsBusiness Wire • 03/02/21
Coronavirus News: Stock Market, Economy Continue Coronavirus ReboundInvestors Business Daily • 02/25/21